Bispecific Antibody Market size was valued at USD 576.44 million in 2024 and is set to reach USD 1.41 billion by the end of 2037, registering around 7.1% CAGR during the forecast period i.e., between 2025-2037. In the year 2025, the industry size of bispecific antibody is assessed at USD 609.64 million.
The market is primarily driven by a rise in the number of cancer-afflicted people. Simply owing to population increase and aging, the worldwide burden of cancer is anticipated to rise to 27.5 million new cases and 16.3 million cancer deaths by 2040. Bispecific antibodies are a type of immunotherapy that has shown promising results in cancer treatment. Also, it can redirect and activate immune cells to specifically target cancer cells.
Besides this, rising facilities for rare diseases can facilitate access to bispecific antibodies for treatment. On May 4, 2023, the National Organization for Rare Disorders (NORD) unveiled the opening of nine additional Rare Disease Centers of Excellence, bringing the total number of medical facilities of NORD in the United States to 40. Rare diseases are typically associated with unmet medical needs, the establishment of specific facilities will increase the need for antibodies for the treatment of rare diseases.
Growth Drivers
Challenges
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
7.1% |
|
Base Year Market Size (2024) |
USD 576.44 million |
|
Forecast Year Market Size (2037) |
USD 1.41 billion |
|
Regional Scope |
|
Indication (Autoimmune Diseases, Oncology)
The oncology segment in the bispecific antibody market is poised to have the largest revenue share of about 65% till 2037. The rise in the development of therapies for cancer is expected to drive the segment’s gain. Since 2000, the number of cancer-targeting clinical studies has nearly quadrupled, rising from 421 in 2000 to 1,489 in 2021. Furthermore, the cases of cancer are predicted to rise in coming years, owing to the obese and unhealthy lifestyle of humans. Excess body weight is responsible for roughly 5% of new cancer cases in men and 10% in women each year. Bispecific antibodies can be combined with targeted agents, such as small molecule inhibitors or monoclonal antibodies, to achieve synergistic effects. By simultaneously targeting tumor cells and specific signaling pathways or growth factor receptors, bispecific antibodies in combination with targeted agents can enhance the anti-cancer activity and overcome resistance mechanisms, improving treatment outcomes.
End-Users (Homecare, Hospitals, Specialty Clinics)
The hospital segment in the bispecific antibody market will accumulate a significant portion of around 46% in the year 2037. Around 25% of patients died in a hospital in the United States, with 62% having been admitted at least once in the previous month. Furthermore, in their last and critical time of life, 29% of patients had been taken to an intensive care unit. They can target specific cancer cells while simultaneously engaging the immune system to enhance anti-tumor immune response. Bispecific antibodies can be administered as part of immunotherapy regimens, such as immune checkpoint inhibitors or CR-T cell therapies, to improve treatment outcomes and patient responses at hospitals.
Our in-depth analysis of the global bispecific antibody market includes the following segments:
|
Drugs |
|
|
Indication |
|
|
End User |
|
North American Market Forecast
The North American region is projected to hold over 35% share of the global bispecific antibody market by the end of 2037, due to rising demand for targeted and personalized therapies. For the previous eight years, personalized medicines have been responsible for at least twenty-five percent of new drug approvals in the United States. Moreover, in 2022, twelve personalized medications have been approved, accounting for about 34 percent of all freshly approved therapeutic molecular entities. This customization enables the development of therapies that are tailored to the molecular profile of a patient’s tumor potentially increasing treatment efficacy and reducing adverse effects. Hence, it is set to drive the expansion of the bispecific antibody market in the region.
APAC Market Statistics
The Asia Pacific bispecific antibody market is estimated to be the 2nd largest, with a share of about 24% by the end of 2037. Rising government initiatives for the treatment of rare diseases. In March 2021, the government announced the National Policy for Rare Diseases (NPRD), 2021 in India, to help patients with rare diseases. The government intends to provide financial assistance of up to USD 61, 146 to individuals suffering from any category of Rare Diseases. Moreover, there is also a provision for proving the treatment in any of the Centre of Excellence falls under NPRD-2021. Such initiatives focused on improving patient access to bispecific antibody treatments for rare diseases. This may include insurance coverage and reimbursement of these therapies, ensuring that patients can afford and access these innovative treatments.
Author Credits: Radhika Pawar
Copyright © 2024 Research Nester. All Rights Reserved
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?